Symbiosis Pharmaceutical Services has completed qualification of its new automated FPD 50 Flexicon fill/finish line at a commercial production facility in Stirling, Scotland. The line features a Grade A Restricted Access Barrier System (RABS) and incorporates technologies including rapid transfer ports for aseptic handling, precision vial filling, and rotary crimping for secure vial closure. This investment aims to enhance technical capabilities and expand sterile manufacturing capacity to meet growing client demand and regulatory standards. Commercial production is expected to begin in Q4 2025, enabling batch sizes up to 15,000 vials, supporting critical therapy availability.